Akebia gets FDA approval of renal anaemia therapy Vafseo
28 Mar 2024
Drug Approval
Akebia Therapeutics gained FDA approval of Vafseo (vadadustat) for the treatment of anaemia due to chronic kidney disease (CKD), but in a narrower patient population than hoped for when it first sought clearance back in 2021.
The original application aimed to gain approval of the once-daily oral HIF-PH inhibitor in both adult patients on dialysis and those not on dialysis. However, the FDA rejected the filing after Vafseo failed to demonstrate non-inferiority with regard to major adverse cardiovascular events (MACE) versus Amgen's Aranesp (darbepoetin alfa) in CKD patients not dependent on dialysis.
While Akebia appealed the decision, the FDA stood firm, but allowed the company to resubmit an application for dialysis dependent patients without the need to conduct further clinical studies. The subsequent filing was made in September last year.
Specifically, the FDA approved Vafseo for the treatment of anaemia due to CKD in adults who have been receiving dialysis for at least three months. The product carries a boxed warning regarding an increased risk of death, myocardial infarction, stroke, venous thromboembolism and thrombosis of vascular access.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.